Lineage Cell Therapeutics, Inc. is launching a new corneal endothelial cell (CEnC) therapy program as part of an expansion of its cell transplant pipeline.
First, a look at Lineage.
Headquartered in Carlsbad, California, the clinical-stage biotechnology company is best known for its development of allogeneic cell therapies intended to treat serious medical conditions.
- Chief among these disease targets: corneal endothelial disease (CED).
The basis for these treatments: Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering (AlloSCOPE), its proprietary cell-based technology platform.
What does this platform do, exactly?
AlloSCOPE manufactures allogeneic, cell-based products derived from a single initial cell line, providing “consistent, cost-effective, and scalable cell-based production” applicable across multiple programs (including CED).
- These products are designed as specialized human cells with key functions similar—or even identical—to those naturally found in the human body.
Explain how the cells are produced.
At the center of this process is “directed differentiation,” in which self-renewing pluripotent stem cells (PSC) are guided to become specific function cell types that can provide an endless supply of starting material.
These cells are intended for transplantation into patients to:
- Replace or support cells that are absent or dysfunctional due to a degenerative disease (such as CED), aging, or a traumatic injury
- Restore or enhance a patient’s functional activity in that target tissue
Importantly: Each PSC includes a ready-to-inject formulation delivered as a one-time treatment (with cell integration without rejection)—and is developed via a scalable process ideal for both clinical and commercial use.
So! How does this new cell therapy program come into play?
Manufactured utilizing Lineage’s AlloSCOPE program, COR1 is a preclinical candidate designed to replace damaged corneal cells and restore corneal function.
- Its investigational indications: Fuch’s endothelial corneal dystrophy (FECD) and bullous keratopathy.
And what’s the plan?
Lineage CEO Brian M. Culley shared that the company intends to produce and provide a "consistent and ‘off-the-shelf’ allogeneic source of CEnCs” into this new clinical program by incorporating key components and development expertise from:
- The AlloSCOPE platform
- Specifically: Its 5D manufacturing process aimed at higher-scale, earlier production with reduced manipulation
- Supported by reported success of current Good Manufacturing Practice (cGMP) production
- The OpRegen program
Remind me: What’s the OpRegen program?
OpRegen (RG6501) is an investigational candidate designed as an allogeneic retinal pigmented epithelial (RPE) cell therapy.
- Its proposed clinical indication: Geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).
- And its purpose: To slow or halt disease progression and preserve (or restore) visual function.
- See here for how it does this (via a subretinal injection).
Notably: The asset’s clinical development and ongoing investigation are being conducted in a global collaboration between Lineage, Roche, and Genentech, a member of the Roche Group.
And that asset has already undergone clinical investigations, right?
Correct. In fact, we reported on phase 1/2 data nearly 3 years ago (April 2023), in which OpRegen-treated retinal pigment epithelial (RPE) cells may benefit remaining retinal cells within atrophic areas by counteracting host RPE cell dysfunction / loss.
- This dataset was followed in June 2025 with 36-month findings, as seen here.
And currently: OpRegen is undergoing phase 2a clinical evaluation in the GAlette study (NCT05626114).
Noted. Circling back to COR1 now … what’s the potential for its impact?
Potentially? Huge. If successful, COR1 could provide a much needed source of CEnCs for corneal transplants—without having to rely on human organ donors.
Also keep in mind: While the success rate of corneal transplants restoring vision using human donor cells is high, the global demand for such transplants—and, as a result, donated human corneas—has become an issue.
- In other words: The demand for corneal transplants across the globe far outweighs the availability of donated corneas (with a shortage of 12.7 million and only 1 in 70 receiving a transplant).
Ah. I see. So where do we go from here?
For COR1? Preclinical testing is up next.
From there, the company has not yet shared further advancement plans for its clinical development.
… so stay tuned.